Evidence-Based Analysis: How Pregnancy Vaccines Provide Safe Protection for Both Mother & Baby Lives 

Nature's Most Advanced Protective System

During pregnancy, the body has a remarkable way of protecting the baby through a process involving the neonatal Fc receptor (FcRn). [7] This receptor acts like a selective gateway, allowing important maternal IgG antibodies to cross the placenta and reach the fetus, helping to build the baby’s immune defenses. This antibody transfer becomes significantly more efficient after 28 weeks of gestation, reaching its highest level during the third trimester. [8]

Evidence-Based Clinical Guide

Major health authorities, including the World Health Organization (WHO), [1] the Centers for Disease Control and Prevention (CDC), [2] and the American College of Obstetricians and Gynecologists (ACOG), [3] continue to strongly recommend vaccination during pregnancy, even amid recent policy debates. [4] A 2022 Nature Communications systematic review involving 117,552 pregnant individuals who received mRNA-based COVID-19 vaccines reported 89.5% effectiveness against infection seven days after the second dose, along with a 15% reduction in stillbirth risk. [5] Meanwhile, a pivotal trial of the respiratory syncytial virus (RSV) vaccine published in The New England Journal of Medicine (NEJM) demonstrated 81.8% efficacy in preventing severe lower respiratory tract illness in infants. [6] Notably, as leading authorities in maternal and perinatal epidemiology, Dr. Deshayne Fell and Prof. Mark Walker have reshaped current understanding of vaccine safety and effectiveness in pregnancy. Their extensive research provides robust evidence supporting the safety of maternal immunization and addresses critical issues related to birth outcomes, neonatal health, and longer-term child wellness. [38 - 52] Prof. Walker's role in founding The Better Outcomes Registry & Network (BORN) Ontario has enabled large-scale, high-quality investigations on vaccination and perinatal health, promoting real-time policy guidance on maternal immunization programs and safety monitoring. [43 & 44]

Vaccination Timing Has a Significant Impact on Antibody Transfer Efficiency

A 2024 study examining RSV vaccination found that administering vaccines at least 5 weeks before delivery resulted in the highest transplacental transfer rates. [9] For COVID-19 vaccines, early third-trimester vaccination (27-31 weeks) produced about 2.3 times higher antibody transfer ratios compared to later vaccination. [10]

The antibody transfer process shows remarkable specificity, with IgG1 antibodies crossing most efficiently, followed by IgG4, IgG3, and IgG2. [11] mRNA vaccines demonstrate superior antibody transfer compared to other platforms, producing higher initial antibody levels and more efficient transplacental transport. [12]

Four Essential Vaccines: What the Latest Evidence Shows

1. COVID-19 vaccination maintains strong medical support despite 2025 policy changes. [4] American College of Obstetricians and Gynecologists (ACOG) issued a forceful statement emphasizing that "COVID infection during pregnancy can be catastrophic." [34] Safety data from hundreds of thousands of pregnant women shows no increase in adverse outcomes. [5] Completion of a two-dose primary mRNA COVID‑19 vaccine series during pregnancy was 61% effective (95% CI: 31%–78%) in preventing hospitalization for infants under 6 months old. Notably, when the series was completed later in pregnancy, effectiveness rose to 80% (95% CI: 55%–91%), compared to 32% (95% CI: –43% to 68%) effectiveness when vaccination occurred earlier in pregnancy. [13] Addotionaly, Multiple large, population-based investigations co-authored by Dr. Fell demonstrated that COVID-19 vaccination during pregnancy does not raise the risk of adverse peripartum outcomes. Effects such as postpartum hemorrhage, chorioamnionitis, cesarean delivery, emergency cesarean, neonatal intensive care unit (NICU) admission, and low Apgar scores (a standardized medical assessment tool used to quickly evaluate the immediate health status of newborn babies at birth) were not significantly elevated in vaccinated compared to unvaccinated or postpartum-vaccinated individuals. [38, 39 & 40] Evidence shows no connection between miscarriage and first-trimester vaccination during pregnancy [45 & 46] and no connection between the third dose (booster) of COVID-19 vaccination during pregnancy and increased risk of adverse pregnancy, fetal, or neonatal outcomes. [41 & 42] Remarkably, infants born to vaccinated mothers had lower rates of severe neonatal morbidity, neonatal death, and Neonatal Intensive Care Unit (NICU) admission compared to those born to unvaccinated mothers. [47]

2. Influenza vaccination remains universally recommended, with research presenting that maternal flu immunization is a vital process for protecting both maternal and neonatal health. Vaccination reduces the risk of influenza-related hospitalization in pregnant individuals by 50–70%. Transplacental antibody transfer provides up to 6 months of passive protection for infants and significantly lowers the incidence of severe respiratory illness. [14], with Dr. Fell's studies confirming that influenza vaccination during pregnancy is highly effective in protecting infants. Across several seasons, effectiveness against laboratory-confirmed influenza infection in infants under 6 months was approximately 64%, and effectiveness against influenza hospitalization reached 67%. [48] While no increased risk of adverse early childhood health outcomes, including hospitalizations or developmental problems, has been linked to maternal seasonal influenza vaccination. [49 & 50]

Over a decade ago, research led by Prof. Walker and Dr. Fell during the 2009–2010 H1N1 pandemic found that maternal H1N1 vaccination reduced the risk of very preterm birth, small-for-gestational-age infants, and fetal death, providing real-world evidence of protective advantages. [51 & 52]

3. Tdap (Tetanus, Diphtheria, and Acellular Pertussis) maternal vaccination during pregnancy is safe, with no evidence of increased risks for adverse pregnancy, birth, or neonatal outcomes, as shown by long-term studies. [53 & 54] Importantly, Tdap maternal vaccination is recommended during the third trimester by both the CDC and ACOG. Real-world data demonstrate that this provides effective protection for infants against pertussis in the first months of life. [15] With high concentrations of maternal pertussis antibodies efficiently transferred to the fetus, providing critical passive protection in the first months of life. [53] Moreover, studies show that 62% to 100% of infants born to vaccinated mothers have protective levels of anti-tetanus and anti-diphtheria IgG, depending on whether the vaccine was administered before or during pregnancy. [15]

4. RSV vaccination represents the newest addition, with Pfizer's RSVpreF vaccine (trade name Abrysvo) as the only RSV vaccine approved by the U.S. Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for use during pregnancy. A single dose of Pfizer's RSV vaccine (Abrysvo) is recommended for eligible pregnant individuals as part of seasonal administration. Eligibility includes individuals between 32 and 36 weeks of gestation during the current respiratory season, who have not planned a delivery within two weeks, and who have not received the maternal RSV vaccine during a previous pregnancy. In a trial involving approximately 3,500 pregnant individuals, Abrysvo reduced the risk of severe lower respiratory tract infections in infants by 81.8% within 90 days and 69.4% within 180 days after birth, compared to the placebo. [35, 36 & 37]

Debunking Safety Myths with Rock-Solid Evidence

Recent, large-scale studies and systematic reviews confirm that several vaccines, most notably influenza (flu) and Tdap (tetanus, diphtheria, and pertussis), are safe to administer during pregnancy. The evidence consistently shows no increased risk of miscarriage, preterm birth, birth defects, or other adverse outcomes for mothers or infants. For example, a 2024 cohort study found that influenza vaccination in successive pregnancies did not raise the risk of adverse perinatal outcomes, even when doses were given less than a year apart. [16] Multiple reviews and health authorities, including the CDC and WHO, affirm that inactivated influenza vaccines can be safely given in any trimester and that maternal vaccination provides protective antibodies to infants, reducing their risk of severe illness. [17 & 18] Similarly, Tdap vaccination during pregnancy has been shown to have no association with chorioamnionitis, preterm birth, or negative infant outcomes and is recommended to protect newborns from pertussis (whooping cough). [19 & 20] These findings are echoed by systematic reviews and meta-analyses, which report no evidence of increased risk for adverse pregnancy outcomes from maternal influenza, Tdap, pneumococcal, or RSV vaccination.

In summary, the safety of recommended vaccines during pregnancy is well established, and these immunizations play a crucial role in protecting both mothers and their babies from serious infectious diseases. [21 & 22]

Winning the Communication Battle Against Hesitancy

Provider recommendations remain the most influential factor in vaccination decisions, with presumptive communication formats showing superior effectiveness. Studies have revealed that strong, presumptive recommendations can dramatically increase vaccination rates. [23] Women receiving provider offers achieved a 61.4% vaccination rate compared to 22.7% without recommendations. Current hesitancy rates vary by vaccine and region, with CDC data showing that 24.7% of pregnant women are "very hesitant" about influenza vaccination, up from 17.5% in the 2019-20 period. [24] However, RSV vaccine acceptance shows encouraging trends, with 52% of adults in 2024 viewing it as effective, up from 42% in 2023. [25]

The Future Is Bright: Emerging Vaccines and Technologies

The landscape of pregnancy vaccination is rapidly advancing, with several promising vaccines in development targeting Group B Streptococcus (GBS), cytomegalovirus (CMV), and other significant perinatal pathogens. These research pipelines are poised to expand protection options for pregnant women and their infants:

• Group B Streptococcus (GBS):

GBS is a leading cause of neonatal sepsis, pneumonia, and meningitis, and it is also associated with preterm birth and stillbirth. Multiple GBS vaccine candidates are in late-stage clinical trials, including MinervaX’s vaccine and Pfizer’s GBS6, which is being evaluated for safety and immunogenicity in pregnant individuals. Modeling studies suggest that a successful GBS maternal vaccine could prevent tens of thousands of infant deaths and stillbirths worldwide each year. [26 - 28] First-in-human studies of new GBS conjugate vaccines began in late 2024, with ongoing trials in the US and South Africa. [14 & 29]

• Cytomegalovirus (CMV):

Cytomegalovirus (CMV) is a widespread virus that often goes unnoticed by those infected. Despite its commonality, it poses serious threats to fetal development, potentially leading to lasting issues like hearing loss, developmental challenges, and neurological damage. A successful vaccine could safeguard infants from these long-term health consequences. [31]

Several vaccine candidates, including mRNA-based vaccines, are in advanced clinical development, aiming to prevent maternal infection and vertical transmission to the fetus. [31 & 32]

Recent research highlights new targets and strategies for more effective CMV vaccines, with ongoing phase III trials and optimism about future licensure. [30, 31 & 33]

• Other Perinatal Pathogens:

• Vaccines targeting Zika virus, malaria, and extraintestinal pathogenic Escherichia coli (ExPEC) are currently in development, aiming to reduce pregnancy complications and neonatal infections. Zika virus is known to cause congenital Zika syndrome, including microcephaly and severe neurological defects. Malaria during pregnancy can lead to maternal anemia, stillbirth, low birth weight, and preterm deliveries. ExPEC is a major cause of neonatal sepsis and meningitis, posing serious risks to newborn survival and long-term health. [14]

• Innovative approaches, including maternal, neonatal, and early infancy vaccines, are being explored to protect the health of mothers and children worldwide. [28]

Evidence Speaks Loudly

Healthcare providers serve as the crucial link between evidence and implementation, with communication strategies proving more important than ever. The medical consensus remains strong in supporting comprehensive pregnancy vaccination, emphasizing the importance of following evidence-based recommendations.

Ready to enhance your expertise in vaccination strategies?

CIMA Health Academy provides comprehensive continuing education programs designed for healthcare professionals seeking evidence-based training in vaccination protocols and patient communication strategies.

Visit CIMA Health Academy today to access expert-led courses that will elevate your clinical skills and improve patient outcomes.

Join the global community of healthcare professionals advancing maternal and child health through evidence-based practice.

Together, we can ensure that every pregnancy receives the protection that science has proven to be effective.

Enjoyed this article?

Share it with your friends on LinkedIn: Protecting Two Lives: The Science Behind Vaccines During Pregnancy
Follow us on LinkedIn for more updates and insights: Cima Care GmbH